Pyxis Oncology (PYXS) Total Current Liabilities (2020 - 2026)
Pyxis Oncology (PYXS) posted quarterly Total Current Liabilities of $21.1 million for Q4 2025, up 19.52% year-over-year from $17.7 million in Q4 2024, and up 9.02% quarter-over-quarter from $19.4 million in Q3 2025.
Pyxis Oncology (PYXS) Total Current Liabilities (2020 - 2026) Analysis & Trends
Pyxis Oncology (PYXS) has reported Total Current Liabilities for 6 consecutive years, with $21.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Current Liabilities rose 19.52% year-over-year to $21.1 million; the TTM figure through Dec 2025 stood at $21.1 million (up 19.52% YoY), while the FY2025 annual figure was $21.1 million, up 19.52% from the prior year.
- Total Current Liabilities improved to $21.1 million in Q4 2025 per PYXS's latest filing, from $19.4 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $31.6 million in Q4 2022 and bottomed at $9.2 million in Q2 2023.
- Historically, Total Current Liabilities has averaged $18.7 million across 5 years, with a median of $18.2 million in 2021.
- Annual changes were most pronounced in 2021 — Total Current Liabilities jumped 407.13% — and 2023, when it tumbled 39.54%.
- Pyxis Oncology's Total Current Liabilities stood at $18.7 million in 2021, then soared by 69.09% to $31.6 million in 2022, then slipped by 18.57% to $25.8 million in 2023, then tumbled by 31.36% to $17.7 million in 2024, then increased by 19.52% to $21.1 million in 2025.
- Business Quant data shows PYXS's Total Current Liabilities at $21.1 million in Q4 2025, $19.4 million in Q3 2025, and $17.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Pyxis Oncology | 199.01 Mn | 166.02 Mn | - | 27.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.47 Mn |
| Dec 31, 2025 | 21.13 Mn |
| Sep 30, 2025 | 19.38 Mn |
| Jun 30, 2025 | 17.68 Mn |
| Mar 31, 2025 | 14.43 Mn |
| Dec 31, 2024 | 17.68 Mn |
| Sep 30, 2024 | 20.32 Mn |
| Jun 30, 2024 | 16.90 Mn |
| Mar 31, 2024 | 14.14 Mn |
| Dec 31, 2023 | 25.76 Mn |
| Sep 30, 2023 | 28.33 Mn |
| Jun 30, 2023 | 9.23 Mn |
| Mar 31, 2023 | 11.60 Mn |
| Dec 31, 2022 | 31.63 Mn |
| Sep 30, 2022 | 19.10 Mn |
| Jun 30, 2022 | 14.92 Mn |
| Mar 31, 2022 | 19.19 Mn |
| Dec 31, 2021 | 18.71 Mn |
| Sep 30, 2021 | 16.84 Mn |
| Dec 31, 2020 | 3.69 Mn |